# The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

> **NCT05741359** · PHASE1 · RECRUITING · sponsor: **Bioray Laboratories** · enrollment: 18 (estimated)

## Conditions studied

- Non-hodgkin Lymphoma,B Cell

## Interventions

- **DRUG:** CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection

## Key facts

- **NCT ID:** NCT05741359
- **Lead sponsor:** Bioray Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-25
- **Primary completion:** 2026-11-20
- **Final completion:** 2027-01-15
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-11-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05741359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05741359, "The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05741359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*